RxDoctor Payments Data

Parikshit Deshmukh, MD

Psychiatry · Ocala, FLNPI 1437395845

Payments from drug & device makers

$344,406in general payments, 2019–2025

Across 468 payments — averaging $735.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avanir Pharmaceuticals, Inc.$158K
  • Acadia Pharmaceuticals Inc$92K
  • Neurocrine Biosciences, Inc.$58K
  • Teva Pharmaceuticals USA, Inc.$21K
  • Otsuka America Pharmaceutical, Inc.$15K
  • Johnson & Johnson$349
  • plus $264 from 5 others

What the payments were for

  • Consulting fees$25,3637%
  • Speaking & faculty fees$281,31382%
  • Travel & lodging$25,5667%
  • Food & beverage$12,1644%
  • Education$10%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$344,406 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$1,246,201
Medicare patients
6,514
Services billed
24,017

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuedextaDextromethorphan Hbr/Quinidine179$267,200
NuplazidPimavanserin Tartrate57$262,999
AustedoDeutetrabenazine22$119,657
Invega SustennaPaliperidone Palmitate22$64,197
Risperidone ErRisperidone Microspheres25$52,377
Divalproex Sodium321$24,285
SecuadoAsenapine18$23,261
Trazodone Hcl652$10,646
Mirtazapine227$8,670
JardianceEmpagliflozin20$6,136
Sertraline Hcl266$5,228
Risperidone129$5,227
Oxcarbazepine73$5,212
Quetiapine Fumarate153$3,716
EliquisApixaban13$3,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Avanir Pharmaceuticals, Inc.Nuedexta$158,054$267,200179 claims
Acadia Pharmaceuticals IncNuplazid$91,826$262,99957 claims
Teva Pharmaceuticals USA, Inc.Austedo$21,183$119,65722 claims
Johnson & JohnsonInvega Sustenna$349$64,19722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →